Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis

• Main Authors: Sana Imran, Moosa Khan, Mohammad Sair, Sarwat Jahan
• Format: Article
• Language: English
• Published: Dow University of Health Sciences 2014-08-01
• Series: Journal of the Dow University of Health Sciences
• Subjects: calcipotriol; betamethasone valerate; plaque psoriasis; psoriasis area severity index (pasi) parameter
• Online Access: http://www.jduhs.com/index.php/jduhs/article/view/116

Objective: Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis. Materials and Methods: This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psoriatic (mild and moderate) patients were included in the study and they were divided into two groups, A and B; 40 patients in each group. The patients of group A were treated by Betamethasone valerate (0.1%) and the patients of group B were treated by Calcipotriol (0.005%). To observe any significant changes, the PASI parameter was applied at the end of study period. Results: Psoriasis severity improvement was monitored by Psoriasis Area Severity Index (PASI). As comparedto day 0, the mean PASI score changes in both treated groups i.e group A (Betamethasone valerate) and groupB (Calcipotriol) was highly significant at day 90 but the changes in mean PASI score was more marked ingroup B. In mild psoriasis, Calcipotriol causes 71.61% improvement in PASI score whereas Betamethasonevalerate causes 63.2% improvement. In moderate psoriasis, Calcipotriol causes 69.21% improvement in PASI score whereas Betamethasone valerate causes 60.44% improvement. Conclusion: Topical Calcipotriol was more effective in improvement of mild and moderate plaque psoriasis as compared to Betamethasone valerate in local population.